DK1263503T3 - Anvendelse af cyanoquinoliner til behandling erller inhibering af tyktarmspolypper - Google Patents

Anvendelse af cyanoquinoliner til behandling erller inhibering af tyktarmspolypper

Info

Publication number
DK1263503T3
DK1263503T3 DK01918367T DK01918367T DK1263503T3 DK 1263503 T3 DK1263503 T3 DK 1263503T3 DK 01918367 T DK01918367 T DK 01918367T DK 01918367 T DK01918367 T DK 01918367T DK 1263503 T3 DK1263503 T3 DK 1263503T3
Authority
DK
Denmark
Prior art keywords
cyanoquinolines
treatment involves
colon polyps
involves inhibition
inhibition
Prior art date
Application number
DK01918367T
Other languages
English (en)
Inventor
Philip Frost
Carolyn M Discafani-Marro
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK1263503T3 publication Critical patent/DK1263503T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Compounds Of Unknown Constitution (AREA)
DK01918367T 2000-03-13 2001-03-06 Anvendelse af cyanoquinoliner til behandling erller inhibering af tyktarmspolypper DK1263503T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52419600A 2000-03-13 2000-03-13

Publications (1)

Publication Number Publication Date
DK1263503T3 true DK1263503T3 (da) 2006-02-13

Family

ID=24088181

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01918367T DK1263503T3 (da) 2000-03-13 2001-03-06 Anvendelse af cyanoquinoliner til behandling erller inhibering af tyktarmspolypper

Country Status (23)

Country Link
EP (1) EP1263503B1 (da)
JP (1) JP2003526686A (da)
KR (2) KR100817423B1 (da)
CN (1) CN1190197C (da)
AR (1) AR035482A1 (da)
AT (1) ATE308364T1 (da)
AU (2) AU2001245452B2 (da)
BR (1) BR0109165A (da)
CA (1) CA2402742C (da)
DE (1) DE60114580T2 (da)
DK (1) DK1263503T3 (da)
EA (1) EA200200976A1 (da)
ES (1) ES2248302T3 (da)
HK (1) HK1048775B (da)
HU (1) HUP0300547A2 (da)
IL (2) IL151249A0 (da)
MX (1) MXPA02008836A (da)
NO (1) NO20024356L (da)
NZ (1) NZ521117A (da)
PL (1) PL202873B1 (da)
TW (1) TWI262805B (da)
WO (1) WO2001068186A2 (da)
ZA (1) ZA200208178B (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
AU2002352878B2 (en) 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
WO2003064399A1 (fr) * 2002-01-28 2003-08-07 Ube Industries, Ltd. Procede de production de derive de quinazolin-4-one
BR0307375A (pt) * 2002-02-05 2004-12-07 Wyeth Corp Processo para a sìntese de ácidos n-acil-2-amino-4-alcóxi-5-nitro-benzóicos
JP2005536462A (ja) * 2002-04-30 2005-12-02 ユン ジン ファーマスーチカル インダストリーズ カンパニー リミテッド カスパーゼ−３阻害剤としてのキノリン誘導体、この製造方法及びこれを含む薬剤学的組成物
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
CA2529611C (en) 2002-12-20 2009-12-15 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
AU2004253967B2 (en) 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
JP2007537238A (ja) 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療のためのピリミジン誘導体
JP2007537230A (ja) 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の処置用のピリミジン誘導体
MXPA06011658A (es) 2004-05-14 2006-12-14 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
WO2006127203A2 (en) * 2005-05-25 2006-11-30 Wyeth Methods of synthesizing 6-alkylaminoquinoline derivatives
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
JP5688877B2 (ja) 2005-11-11 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌疾患の治療用キナゾリン誘導体
DE102006029446A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Neue 3-substituierte-Chinoline als Kinase-Inhibitoren
DE102006029445A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Neue 3-Cyano-chinoline als Kinase-Inhibitoren
AU2007299080B2 (en) 2006-09-18 2013-04-18 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
DE102007024470A1 (de) 2007-05-24 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren
EP2072502A1 (de) 2007-12-20 2009-06-24 Bayer Schering Pharma Aktiengesellschaft Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
CN102625799A (zh) 2009-06-25 2012-08-01 安姆根有限公司 杂环化合物及其用途
PT2451445T (pt) 2009-07-06 2019-07-10 Boehringer Ingelheim Int Processo para secagem de bibw2992, dos seus sais e de formulações farmacêuticas sólidas compreendendo este ingrediente ativo
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
JP6533997B2 (ja) * 2014-12-26 2019-06-26 株式会社ヤクルト本社 Ｚｎｆ１４３阻害活性を有する化合物およびその利用
ES2898765T3 (es) * 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
WO2017058805A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
KR20180081596A (ko) 2015-11-16 2018-07-16 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
CN110869357A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 化合物及其用于治疗癌症的使用方法
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
MX2021000887A (es) 2018-08-01 2021-03-31 Araxes Pharma Llc Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
WO2026017799A1 (en) * 2024-07-18 2026-01-22 Centre Hospitalier Universitaire Vaudois Substituted 3-cyanoquinolines for the prevention and treatment of sexually transmitted diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
HUP0203162A3 (en) * 1999-08-12 2006-07-28 Wyeth Holdings Corp Madison Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer

Also Published As

Publication number Publication date
ZA200208178B (en) 2004-02-11
DE60114580D1 (de) 2005-12-08
AR035482A1 (es) 2004-06-02
AU4545201A (en) 2001-09-24
CA2402742A1 (en) 2001-09-20
EP1263503A2 (en) 2002-12-11
KR20020092987A (ko) 2002-12-12
IL151249A (en) 2008-06-05
KR20080009294A (ko) 2008-01-28
CN1190197C (zh) 2005-02-23
NZ521117A (en) 2005-02-25
NO20024356L (no) 2002-11-12
WO2001068186A3 (en) 2002-01-17
JP2003526686A (ja) 2003-09-09
TWI262805B (en) 2006-10-01
EA200200976A1 (ru) 2003-02-27
AU2001245452B2 (en) 2005-05-05
HK1048775B (en) 2006-01-20
CN1429126A (zh) 2003-07-09
PL202873B1 (pl) 2009-07-31
HUP0300547A2 (hu) 2003-07-28
IL151249A0 (en) 2003-04-10
EP1263503B1 (en) 2005-11-02
HK1048775A1 (en) 2003-04-17
KR100817423B1 (ko) 2008-03-27
NO20024356D0 (no) 2002-09-12
WO2001068186A2 (en) 2001-09-20
MXPA02008836A (es) 2003-02-10
ATE308364T1 (de) 2005-11-15
CA2402742C (en) 2009-05-12
BR0109165A (pt) 2003-04-22
DE60114580T2 (de) 2006-07-27
PL363072A1 (en) 2004-11-15
ES2248302T3 (es) 2006-03-16

Similar Documents

Publication Publication Date Title
DK1263503T3 (da) Anvendelse af cyanoquinoliner til behandling erller inhibering af tyktarmspolypper
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
DK1343773T3 (da) Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
NO20030230L (no) Behandling av jernsulfidavsetninger
DK1292594T3 (da) Quinazolinderivater til behandling af tumorer
DK1294644T3 (da) Vandbehandlingssammensætninger
DK1143977T3 (da) 2-oxy-benzoxazinonderivater til behandling af obesitas
DK1324970T3 (da) Retinoider til behandling af emfysem
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1499730T3 (da) Immunokonjugater til behandling af tumorer
DK1176964T3 (da) Brug af ET743 til behandling af cancer
DK1282616T3 (da) Hydroxyphenylpiperidin-4-ylidenmethylbenzamidderivater til behandling af smerter
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
DK1206436T3 (da) Retinoider til behandling af emfysem
DK1344526T3 (da) Midler til forebyggelse/behandling af inflammatoriske luftvejslidelser
DK1197485T3 (da) Cyclobutendionderivater til behandling af artherosclerose
NO20026219L (no) Forbindelser for behandling av svekket fundisk relaksasjon
DK1350521T3 (da) Immunoterapeutiske kombinationer til behandling af tumorer
DK1200114T3 (da) PPAR delta inhibitorer til behandling af kardiovaskulære sygdomme
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
DK1468996T3 (da) Indolderivater til behandling af CNS-sygdomme
FR2805983B3 (fr) Douche
DK1200447T3 (da) Oxazinocarbazoler til behandling af CNS-sygdomme
DK1468686T3 (da) S-methyl-dihydro-ziprasidon til behandling af psykiatriske lidelser